MAPRE3 and chromophobe renal cell carcinoma: Using IHC, we next independently confirmed and validated biomarker specificity including CCND1 protein overexpression in gene fusion-positive ROs, MAPRE3, and ADGRF5 (also identified in the glycoproteomics analysis) expression in all RO subtypes (Figure 7D) and GPNMB in chRCC.